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uvenile dermatomyositis (JDM) is a rare disease that belongs
o the group of idiopathic inﬂammatory myopathies.1 Clin-
cally amyopathic dermatomyositis (CADM) is an even rarer
ntity in pediatrics, with only 75 cases described in the
iterature.2 CADM patients present mild or no muscle involve-
ent and the cutaneous manifestations are indistinguishable
rom those seen in classical dermatomyositis (DM).3,4
Systemic inﬂammatory vasculopathy is an important char-
cteristic of JDM affecting especially the microcirculation.5
ailfold capillaroscopy (NFC) is a non-invasive method
6Please cite this article in press as: Campos LM, et al. Improvement of nail
a child with clinically amyopathic juvenile dermatomyositis. Rev Bras Reu
hat allows the direct visualization of nailfold capillaries.
ecreased number of capillary loops (devascularization) asso-
iated with enlarged capillaries and branching capillary loops
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icenses/by-nc-nd/4.0/).are the most characteristic ﬁndings observed in JDM.7 In addi-
tion, several studies have described an association between
NFC abnormalities and JDM severity and activity.8 To the
best of our knowledge, NFC abnormalities have not been sys-
tematically studied in CADM. We  describe herein the case
of a 4-year-old child diagnosed with juvenile CADM with
important changes in NFC, whose response to treatment was
followed by signiﬁcant improvement in capillaroscopy abnor-
malities.
Case  reportfold capillary microangiopathy after immunosuppressant therapy in
matol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.05.002
In June 2008, a 4-year-old girl was attended with a four months
complaint of malar rash, photosensitivity, and erythematous
lesions over the proximal interphalangeal joints, elbows and
e under the CC BY-NC-ND license (http://creativecommons.org/
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Table 1 – Sequential capillaroscopic evaluation performed from June 2008 to October 2013 in a patient with Juvenile
Amyopathic Dermatomyositis.
Capillaroscopy parameters (mean value for ten ﬁngers)
Branched capillary
loops
Dilated capillary
loopsa
Megacapillary
loopsb
Number of capillary
loops/mm
Avascular
scorec
June/2008 0.2 3.6 0.1 5.2 2.0
February/2009 0.0 2.1 0.0 5.7 1.8
November/2009 0.1 1.6 0.0 5.7 1.7
December/2010 0.4 0.5 0.0 8.2 0.2
November/2011 0.0 0.2 0.0 8.7 0.1
November/2012 0.0 0.0 0.0 9.6 0.0
October/2013 0.0 0.0 0.0 9.7  0.0
a The three limbs of the capillary loop should be enlarged over 4 times.
b The three limbs of the capillary loop should be enlarged over 10 times.
 capil
 grade
remained on remission, MMT  80/80, CMAS 51/52, muscu-
lar DAS 0/11, cutaneous DAS 0/9, normal ESR and CRP,
aldolase 5.1 IU/L, CK 115 IU/L, LDH 400 IU/L, AST 20 IU/L, and
Fig. 1 – Capillaroscopy (June, 2008). Nailfold capillaroscopyc Avascular area is deﬁned as the lack of more than two successive
avascular areas); grade 2 (more than two discrete avascular areas);
knees, with no complaints regarding muscle strength loss or
pain. The Manual Muscle Testing (MMT)9 score was 80/80,
Childhood Myositis Assessment Scale (CMAS)9 was 48/52,
muscular Disease Activity Score (DAS) was 2/11 and cutaneous
DAS was 6/9.10 Laboratory tests showed hemoglobin 13.6 g/L,
hematocrit 38.5%, leukocytes 21,000/mm3 (76% neutrophils,
16% lymphocytes), platelets 289,000/mm3, erythrocyte sedi-
mentation rate (ESR) 23 mm/1st hour, C-reactive protein(CRP)
undetectable, aldolase 20.8 IU/L (normal < 7.6), creatine kinase
(CK) 130 IU/L (normal < 204), lactate dehydrogenase (LDH)
575 IU/L (normal < 480), aspartate aminotransferase (AST)
29 IU/L (normal < 34), alanine aminotransferase (ALT) 14 IU/L
(normal < 44), and positive antinuclear antibody (1/640, homo-
geneous ﬁne speckled pattern). Capillaroscopy was performed
in all ﬁngers of both hands using a stereomicroscope (Olym-
pus SZ40) at 10× to 16× magniﬁcation under epi-illumination
at 45◦, analyzing number of capillary/mm, enlarged, giant and
branched capillaries, and avascular score.11 Capillaroscopy
showed a scleroderma (SD) pattern, with severe microan-
giopathy, characterized by decreased number of the capillary
loops with intense avascular areas, few branching and
frequent dilated capillary loops (Table 1; Fig. 1). Clinically amy-
opathic dermatomyositis (CADM) diagnosis was established,3
since Bohan and Peter criteria were not fulﬁlled.12 Treat-
ment with prednisolone (0.5 mg/kg/day), hydroxychloroquine
(5 mg/kg/day), and photoprotection was then introduced.
After four months, the patient persisted with disease activ-
ity. Muscle magnetic resonance imaging (MRI) and muscle
biopsy were normal. Electromyography was not performed.
Hydroxychloroquine dose was increased, and methotrex-
ate (0.5 mg/kg/week), folic acid and topical tacrolimus were
associated, with partial improvement of symptoms, which
allowed gradual reduction of prednisolone dose. In July 2009,
the patient started complaining of fatigue and new Got-
tron’s papules and elevation of LDH serum levels (666 IU/L)
were observed. Prednisolone and methotrexate doses were
increased and thalidomide (50 mg/day) was introduced with
satisfactory response. In October 2009, the patient was con-Please cite this article in press as: Campos LM, et al. Improvement of nail
a child with clinically amyopathic juvenile dermatomyositis. Rev Bras Reu
sidered in clinical remission, with MMT  80/80, CMAS 48/52,
muscular DAS 1/11, cutaneous DAS 0/9, normal ESR and CRP,
aldolase 8.7 IU/L, CK 64 IU/L, LDH 524 IU/L, AST 22 IU/L, and ALT
18 IU/L. Capillaroscopy presented slight improvement. At thislary loops; grade 0 (no avascular area); grade 1 (one or two discrete
 3 (extensive and coalescent avascular areas).
moment, hydroxychloroquine was discontinued, followed by
withdrawal of topical tacrolimus (February 2010), prednisolone
(April 2010), methotrexate (December 2010), and thalidomide
(July 2011).
At her last appointment (October 2013), the patientfold capillary microangiopathy after immunosuppressant therapy in
matol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.05.002
showing presence of dilated and branched capillaries
(arrows) (Fig. 1A), and avascular areas (Fig. 1B) (arrows) in
the second and fourth digit from the left hand respectively
(15× magniﬁcation).
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Fig. 2 – Capillaroscopy (October, 2013). Nailfold
capillaroscopy showing a normal pattern, with a normal
number of capillaries/mm, no dilated or megacapillaries
and revascularization of avascular areas in the second and
fourth digit from the left hand respectively (15×
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aagniﬁcation) (Fig. 2A and B).
LT 14 IU/L. Capillaroscopy was normal, showing signiﬁcant
mprovement in the microangiopathy, normal number of cap-
llaries/mm, no avascular areas and no branching or dilated
apillary loops (Table 1; Fig. 2).
iscussion
his is the ﬁrst report on the presence of exuberant periph-
ral microangiopathy evaluated by NFC in a child with CADM,
ollowed by a progressive and signiﬁcant improvement of NFC
hanges after successful immunosuppressive treatment.
Although there are not studies reporting the dynamic
ature of NFC microangiopathic abnormalities (dilated cap-
llary loops, megacapillaries and avascular areas) and its
orrelation with disease activity in CADM patients, as
escribed in the case presented herein, this aspect has been
bserved in several studies including classical JDM.7,8 Capil-
aroscopy was evaluated in 61 JDM children over 36 months.
he improvement in the number of loops/mm was associated
ith less intense cutaneous activity and monocyclic diseasePlease cite this article in press as: Campos LM, et al. Improvement of nail
a child with clinically amyopathic juvenile dermatomyositis. Rev Bras Reu
ourse. On the other hand, polycyclic disease was associated
ith maintenance of cutaneous activity and persistent cap-
llaroscopy changes. There was no correlation between NFC
nd muscle disease activity, suggesting that there are different 6;x  x x(x x):xxx–xxx 3
mechanisms underlying the pathogenesis of skin and muscle
in JDM vasculopathy.13 Although NFC abnormalities are not
included in JDM classiﬁcation criteria,12 they seem to reﬂect
systemic vasculopathy, and some authors suggest its inclu-
sion among classiﬁcation criteria for JDM.14 Since CADM could
be considered part of the spectrum of JDM, it could be assumed
that both situations share the same NFC behavior.
In the present case, the patient was diagnosed as CADM,
most speciﬁcally the subphenotype denominated juvenile
hypomyopathic dermatomyositis (HDM), which designation
is applied for patients with cutaneous DM and no clinical
evidence of muscle disease (i.e. weakness), whose sub-
clinical evidence of myositis upon laboratory (e.g. muscle
enzymes), electrophysiological, and/or radiological evaluation
is found during investigation.3,4 In fact, she presented major
skin disease manifestations associated with slight increased
muscle enzymes (aldolase and LDH), but without muscle
complaints or weakness. Muscular activity scores were con-
sidered as within the normal ranges.15 The small decrease
in CMAS observed in this patient at disease presentation
may be attributed to her early age and lack of cooperation
in carrying out some of the exercises required. The nor-
mal  results of MRI and muscle biopsy could be partially
affected by the low-dose corticosteroid use, since this ther-
apy had been initiated four months before these tests were
performed.
In a review describing 68 cases of juvenile CADM, 56% was
classiﬁed as amyopathic DM(ADM), 18% as HDM and 26% pro-
gressed to classical JDM after a median follow up of 1.9 years.
However, it was not possible to determine the parameters that
could predict the outcome of patients with CADM to the clas-
sic form of JDM. Calcinosis was present in less than 5% of
the cases and no children had cutaneous or gastro-intestinal
vasculitis, pulmonary infarction, interstitial pneumonitis or
malignancy, which suggests a good prognosis for this variant
of JDM.2
The best therapeutic option in CADM is still controver-
sial, since there are no randomized studies in this ﬁeld.
Some authors argue that early use of corticosteroids and
immunosuppressive drugs could prevent progression to JDM.
Alternatively, in a review of juvenile CADM treatment, the
authors concluded that only photoprotection, topical med-
ications and oral hydroxychloroquine should be initially
used and corticosteroids and immunosuppressant therapy
should be reserved for refractory cases.2,16 Our patient pre-
sented severe skin manifestations and the use of concomitant
photoprotection, topical therapy, hydroxychloroquine and
immunosuppressant drugs was necessary. However, resolu-
tion of the skin and capillaroscopic abnormalities was more
clearly attained after the introduction of thalidomide. Indeed,
the efﬁcacy of thalidomide in the treatment of refractory forms
of JDM, as well in CADM, has been previously described.17
Due to the dynamic characteristics of NFC changes in
JDM compared to other autoimmune rheumatic diseases, NFC
seems to be a useful tool for the follow-up and in monitoring
treatment response in this group of patients. Although NFC
has not been systematically studied in CADM, the presentfold capillary microangiopathy after immunosuppressant therapy in
matol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.05.002
report suggests that NFC can also be used as a convenient
prognostic and monitoring parameter for the skin involve-
ment in these patients.
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